Simvastatin in the treatment of atherosclerosis


Cite item

Full Text

Abstract

Statins (inhibitors of HMG-CoA reductase) are the class of lipid-lowering drugs with a large amount of evidence-based data, confirming its efficiency on lipid lowering and decreasing of cardiovascular and total mortality. Statins can slow the progression of atherosclerosis, decrease coronary and periphery atherosclerosis, and also have anti-ischemic, anti-inflammatory, antithrombotic and other effects. Now simvastatin is one of the most frequently used statins. This review summarizes data on its clinical efficiency in atherosclerosis treatment.

About the authors

L O Minushkina

L O Minushkina

References

  1. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48.
  2. Garcia-de-la-Puente S, Luis Arredondo-Garcia J, Gutierrez-Castrellon P, et al. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol 2009.
  3. Torpet LA, Kragelund C, Reibel J, et al. Oral Adverse Drug Reactions To Cardiovascular Drugs. Crit Rev Oral Biol Med 2004;15(1):28-46.
  4. Nägele H, Behrens S, Hashagen S, et al. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. Drug Metabol Drug Interact 2007;22(2-3):195-200.
  5. Assmann G, Kannenberg F, Ramey DR, et al. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24(1):249-59.
  6. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008;62(4):539-54.
  7. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26(11):1758-73.
  8. Vo AN, Kashyap ML. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Rev Cardiovasc Ther 2008;6(10):1303-10.
  9. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008;101(10):1428-36.
  10. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8(2):69-81.
  11. de Sauvage Nolting PR, Buirma RJ, Hutten BA, et al. Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH). Atherosclerosis 2002;164(2):347-54.
  12. Mohrschladt MF, de Maat MP, Westendorp RG, et al. C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy. Atherosclerosis 2001;157(2):491-94.
  13. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
  14. Shafiq N, Bhasin B, Pattanaik S, et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther 2007;45(10):548-55.
  15. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102(15):1748-54.
  16. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344(8923):633-38.
  17. Jensen LO, Thayssen P, Pedersen KE, Haghfelt T, et al. Effect of simvastatin on coronary flow reserve in patients with atherosclerosis and hypercholesterolemia: an intracoronary Doppler study. Coron Artery Dis 2006;17(1):51-56.
  18. Mizuno K, Nakamura H, Ohashi Y, et al. A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study. Clin Ther 2004;26(6):878-88.
  19. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;(4):CD000123.
  20. Terry JG, Carr JJ, Kouba EO, et al. Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am J Cardiol 2007;99(12):1714-17.
  21. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001;155(1):245-50.
  22. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46(1):106-12.
  23. Gottlieb I, Agarwal S, Gautam S, Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy. J Cardiovasc Med (Hagerstown) 2008;9(7):700-06.
  24. Duman D, Demirtunc R, Sahin S, et al. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. J Cardiovasc Med (Hagerstown) 2007;8(12):1007-11.
  25. Nolting PR, de Groot E, Zwinderman AH, et al. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med. 2003;163(15):1837-41.
  26. Smilde TJ, van den Berkmortel FW, Wollersheim H, et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000;30(6):473-80.
  27. Wang L, Rockwood J, Zak D, et al. Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 2008;6(2):149-52.
  28. Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. J Cardiol 2007;100(9):1397-99.
  29. Peng DD, Li ZL.Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome Nan Fang Yi Ke Da Xue Xue Bao. 2008 Mar;28(3):475-7
  30. Jialal I, Miguelino E, Griffen SC, et al. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab 2007;92(8):3136-40.
  31. Cuccurullo C, Iezzi A, Fazia ML, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006;26(12):2716-23.
  32. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91(11):4489-96.
  33. Yip HK, Sun CK, Chang LT, et al. Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies. Int J Cardiol 2007;121(3):253-60.
  34. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-89.
  35. Herman WH, Alexander CM, Cook JR, et al. Effect of Simvastatin Treatment on Cardiovascular Resource Utilization in Impaired Fasting Glucose and Diabetes: Findings from the Scandinavian Simvastatin Survival Study Diabetes Care 1999;22(11):1771-78.
  36. Huskey J, Lindenfeld J, Cook T, et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease Findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 2008.
  37. Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
  38. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45(4):645-54.
  39. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other highrisk conditions. Lancet 2004;363:757-67.
  40. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007;100(7):1047-51.
  41. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2291&mid=1085056570&magid=172&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies